Related Experiment Videos
Anti-integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications
1Albany College of Pharmacy, 106 New Scotland Avenue, Albany, NY 12208-3492, USA. mousas@acp.edu
Abstract:
The role of integrin and extracellular matrix proteins in various pathological processes (including angiogenesis, thrombosis, apoptosis and cell migration and proliferation), leading to both acute and chronic disease states (e.g. ocular diseases, metastasis, unstable angina, myocardial infarction, stroke, osteoporosis, a wide range of inflammatory diseases, vascular remodeling and neurodegenerative disorders) has been recently documented. A key success in this field is evident from the potential role of the platelet GPIIb/IIIa (alphaIIbbeta3) integrin in the prevention, treatment and perhaps diagnosis of various thromboembolic disorders. Additionally, progress has been shown in the development of leukocyte alpha4beta1 antagonists for various inflammatory indications and alphav integrin antagonists for angiogenesis and vascular-related disorders. However, the exact modes of action of certain integrin antagonists are still not fully clear. Integrin antagonists in clinical or pre-clinical development are expected to be used as a stand-alone therapy or, better, as an adjunct to other pharmacotherapy, radiotherapy or interventional procedures.
Insights
Integrin antagonists show promise in treating diseases like thrombosis and inflammation. Further research is needed to clarify their mechanisms and optimize their use alongside other therapies.
Area of Science:
- Biochemistry
- Cell Biology
- Pharmacology
Background:
- Integrins and extracellular matrix proteins are implicated in numerous pathological processes.
- These processes include angiogenesis, thrombosis, apoptosis, cell migration, and proliferation, contributing to various acute and chronic diseases.
- Examples of associated diseases include ocular conditions, metastasis, thromboembolic disorders, inflammatory diseases, vascular remodeling, and neurodegenerative disorders.
Purpose of the Study:
- To review the documented role of integrins and extracellular matrix proteins in pathological processes.
- To highlight successes in developing integrin antagonists for specific conditions.
- To identify areas where further understanding of integrin antagonist mechanisms is required.
Main Methods:
- Literature review of existing research on integrins and extracellular matrix proteins.
- Analysis of clinical and pre-clinical data on integrin antagonist development.
- Synthesis of information regarding therapeutic applications and mechanisms of action.
Main Results:
- Platelet GPIIb/IIIa (alphaIIbbeta3) integrin shows potential in preventing, treating, and diagnosing thromboembolic disorders.
- Leukocyte alpha4beta1 antagonists are being developed for inflammatory indications.
- Alphav integrin antagonists are being explored for angiogenesis and vascular-related disorders.
Conclusions:
- Integrin antagonists represent a promising therapeutic avenue for a range of diseases.
- Further elucidation of the exact modes of action for certain integrin antagonists is necessary.
- Integrin antagonists are expected to be used as standalone or adjunct therapies in clinical practice.